Vaxcyte (PCVX) Current Deferred Revenue (2019 - 2020)
Vaxcyte (PCVX) posted quarterly Current Deferred Revenue of $14000.0 for Q4 2020, down 26.32% year-over-year from $19000.0 in Q1 2020, and down 48.15% quarter-over-quarter from $27000.0 in Q3 2020.
Vaxcyte (PCVX) Current Deferred Revenue (2019 - 2020) Analysis & Trends
Vaxcyte (PCVX) has reported Current Deferred Revenue for 2 consecutive years, with $14000.0 the latest figure, recorded in Q4 2020.
- In Q4 2020, Current Deferred Revenue fell 26.32% year-over-year to $14000.0; the TTM figure through Dec 2020 stood at $14000.0 (down 26.32% YoY), while the FY2020 annual figure was $14000.0, down 26.32% from the prior year.
- Current Deferred Revenue eased to $14000.0 in Q4 2020 per PCVX's latest filing, from $27000.0 in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $27000.0 in Q3 2020 and bottomed at $14000.0 in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Vaxcyte | 8.41 Bn | 8.41 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | 14,000.00 |
| Sep 30, 2020 | 27,000.00 |
| Jun 30, 2020 | 25,000.00 |
| Dec 31, 2019 | 19,000.00 |